Vinorelbine tartrate injection

DRUG4 trials

Sponsors

RemeGen Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Shanghai Yizhong Pharmaceutical Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Conditions

Advanced MalignanciesBreast CancerMetastatic Breast CancerMetastatic Breast Cancer (MBC)Recurrent Breast Cancer

Phase 1

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

RecruitingNCT06202261

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Advanced Malignancies, Metastatic Breast Cancer, Recurrent Breast Cancer

Start: 2023-04-13End: 2027-10-31Target: 154Updated: 2024-03-12

Phase 3

A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

RemeGen Co., Ltd.Breast Cancer

Start: 2020-09-29End: 2024-12-30Target: 366Updated: 2024-01-24

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

RecruitingNCT06079983

Jiangsu Alphamab Biopharmaceuticals Co., LtdBreast Cancer

Start: 2023-12-01End: 2029-03-01Target: 400Updated: 2025-09-12

Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

RecruitingNCT06143553

Shanghai Yizhong Pharmaceutical Co., Ltd.Metastatic Breast Cancer (MBC)

Start: 2023-09-25End: 2025-12-31Target: 168Updated: 2024-11-29

Related Papers

Efficacy and safety results of TQB2930, a HER2-targeted bispecific antibody combined with chemotherapy in patients with HER2-positive breast cancer (BC) previously treated with ≥2 line treatments: Results from a phase 1b/2 study.

Journal of Clinical Oncology2025-05-28

Preliminary safety and efficacy of TQB2930, a HER2-targeted bispecific antibody in patients with advanced breast cancer: Results from a phase 1b study.

Journal of Clinical Oncology2024-06-013 citations